Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 5Phase NA 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 45Uterine Cervical Neoplasms 24Endometrial Neoplasms 24Fallopian Tube Neoplasms 18Breast Neoplasms 13Pancreatic Neoplasms 7Carcinoma, Ovarian Epithelial 7Uterine Cervical Dysplasia 6Sarcoma 6Lung Neoplasms 6Colorectal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 5Colonic Neoplasms 5Stomach Neoplasms 4Melanoma 4Head and Neck Neoplasms 4Brain Neoplasms 4Uterine Neoplasms 3Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Liver Neoplasms 3Carcinoma, Renal Cell 3Vulvar Neoplasms 2Urinary Bladder Neoplasms 2Turcot syndrome 2Triple Negative Breast Neoplasms 2Recurrence 2Rectal Neoplasms 2Peritoneal Neoplasms 2

Interventions

disitamab vedotin 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Ovarian Cancer Recurrent × Gynecologic × Clear all
NCT06660511 2024-10-28

Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

Second Xiangya Hospital of Central South University

Phase EARLY_PHASE1 Recruiting
5 enrolled
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡